GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...
Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...
New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
The European Medicines Agency has started a review of medicines containing finasteride and dutasteride following concerns ...
Russian attackers were behind the hack of the European Medicines Agency EMA in 2020. They had “unauthorized access to ...
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) ...
Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...